MedTrace Logo

Remimazolam vs Propofol in Laser Burn Cases

NCT07213544 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2025-11-20

No results posted yet for this study

Summary

This randomized, single-blind, crossover study compares remimazolam and propofol for monitored anesthetic care during fractional ablative CO₂ laser therapy for burn scars. The primary aim is to assess incidence of respiratory depression, defined as a need for advanced airway maneuvers (jaw thrust/chin lift, insertion of oral or nasal airway, or bag mask ventilation), and hypopnea (respiratory rate \< 8).

Conditions

  • Burn Scar
  • Hypertrophic Scarring
  • Procedural Sedation

Interventions

DRUG

Remimazolam besylate

Remimazolam

DRUG

Propofol

Propofol

Sponsors & Collaborators

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Rishi Patel, MD · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-12
Primary Completion
2027-01-01
Completion
2027-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07213544 on ClinicalTrials.gov